EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE 300 U/ML (GLA-300) IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES AND RENAL IMPAIRMENT: A SUBGROUP ANALYSIS OF ATOS STUDY

被引：0
|
作者：
Tirosh, A. [1 ]
Khan, N. [2 ]
Vargas-Uricoechea, H. [3 ]
Mabunay, M. A. N. [4 ]
Coudert, M. [5 ]
Pilorget, V. [6 ]
Galstyan, G. [7 ]
机构：
[1] Tel Aviv Univ, Div Endocrinol Diabet & Metab, Chaim Sheba Med Ctr, Tel Hashomer, Israel
[2] Imperial Coll London, Ctr Diabet, Al Ain, U Arab Emirates
[3] Univ Cauca, Dept Internal Med, Popayan Cauca, Colombia
[4] Sanofi, Gen Med, Singapore, Singapore
[5] Sanofi, Biostat & Programming, Paris, France
[6] Sanofi, Diabet & Cardiovasc Dev R&D, Paris, France
[7] Minist Russian Federat, Endocrinol Res Ctr Hlth Care, Diabet Foot Dept, Moscow, Russia
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2022年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP049 / #2
引用
收藏
页码：A100 / A101
页数：2
相关论文
共 50 条
  • [31] Impact of Background Antihyperglycemic Therapy on Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naive People with T2DM from the BRIGHT Randomized Study
    Roussel, Ronan
    Rosenstock, Julio
    Pettus, Jeremy
    Ritzel, Robert
    Cheng, Alice
    Bosnyak, Zsolt
    Devisme, Christine
    Cali, Anna M.
    Wang, Xiangling
    Bolli, Geremia B.
    DIABETES, 2018, 67
  • [32] Glycemic Control and Hypoglycemia Benefits with Insulin Glargine 300 U/mL (Gla-300) Extend to People with Type 2 Diabetes (T2DM) and Mild-to-Moderate Renal Impairment
    Escalada, Javier
    Halimi, Serge
    Senior, Peter A.
    Bonnemaire, Mireille
    Cali, Anna M. G.
    Chevalier, Soazig
    Karalliedde, Janaka
    Ritzel, Robert A.
    DIABETES, 2016, 65 : A18 - A18
  • [33] Real-World Safety and Effectiveness of Insulin Glargine 300 U/mL (Gla-300) in People with Type 2 Diabetes (T2DM) Who Fast during Ramadan: Regional Analysis of the ORION Study
    Hassanein, Mohamed
    Buyukbese, Mehmet A.
    Malek, Rachid, Sr.
    Pilorget, Valerie
    Naqvi, Mubarak
    Berthou, Baptiste
    Shaltout, Inass
    Sahay, Rakesh
    DIABETES, 2020, 69
  • [34] ACHIEVE Study: Comparison of Glargine 300 U/ml (Gla-300) with First-Generation Basal Insulin Analogs in insulin-naive Patients with Type-2-Diabetes (T2D) and impaired Kidney Function
    Meneghini, Luigi F.
    Vonbank, Alexander
    Cheng, Alice
    Evenou, Pierre
    Gill, Jas
    Mohamed, Ayad Djala
    Umpierrez, Guillermo
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S366 - S366
  • [35] COMPARATIVE COST AND SAVING ANALYSIS OF INSULIN GLARGINE-300U/ML (GLA-300) VS INSULIN DEGLUDEC 100 U/ML IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS BASED ON THE BRIGHT
    Safia, M.
    Hachelaf, Z.
    Aissaoui, A.
    Mahieu, A.
    Abdul, Jabbar O. A.
    VALUE IN HEALTH, 2024, 27 (12) : S123 - S123
  • [36] Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes after failure of oral therapy in a real-world setting
    Pfohl, Martin
    Jornayvaz, Francois R.
    Fritsche, Andreas
    Pscherer, Stefan
    Anderten, Helmut
    Pegelow, Katrin
    Seufert, Jochen
    DIABETES OBESITY & METABOLISM, 2020, 22 (05): : 759 - 766
  • [37] Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
    Dirk Müller-Wieland
    Nick Freemantle
    Riccardo C. Bonadonna
    Celine Mauquoi
    Gregory Bigot
    Mireille Bonnemaire
    Pierre Gourdy
    Didac Mauricio
    Diabetes Therapy, 2023, 14 : 401 - 413
  • [38] Real-world outcomes in people with type 2 diabetes (PWD2) and renal impairment receiving insulin glargine 300 U/mL (Gla-300) and insulin degludec 100U/mL or 200U/mL (IDeg): the DELIVER-R study
    Bailey, Timothy
    Urquhart, Scott
    Westerbacka, Jukka
    Gill, Jasvinder
    Nicholls, Charlie
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2022, 128 : S59 - S59
  • [39] Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
    Mueller-Wieland, Dirk
    Freemantle, Nick
    Bonadonna, Riccardo C.
    Mauquoi, Celine
    Bigot, Gregory
    Bonnemaire, Mireille
    Gourdy, Pierre
    Mauricio, Didac
    DIABETES THERAPY, 2023, 14 (02) : 401 - 413
  • [40] Is hypoglycaemia a modifiable patient risk in type 2 diabetes: A pooled analysis of insulin glargine 300 U/mL (Gla-300) vs 100U/mL (Gla-100) trials?
    Zhang, Q.
    Rosenstock, J.
    Gerrits, C.
    Liao, L.
    Chew, P.
    DIABETOLOGIA, 2015, 58 : S472 - S472
12345